Trial · NCT00378326

Immunotherapy of the Paraneoplastic Syndromes

NCT00378326, Not applicable, Completed, Rockefeller University; results first posted 2016-02-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Immunotherapy of the Paraneoplastic Syndromes. Trials, record NCT00378326. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00378326

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Immunotherapy of the Paraneoplastic Syndromes
NCT number: NCT00378326
Status: Completed
Phases: Not applicable
Enrollment: 26 participants, actual
Lead sponsor: Rockefeller University
Conditions: Paraneoplastic Syndromes
Interventions: Tacrolimus
First posted: 2006-09-20
Last updated: 2023-09-18
Results first posted: 2016-02-23

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus	through study completion, median 3 years of follow up	Survival in patients with paraneoplastic disease who are treated with Tacrolimus, from time of tacrolimus treatment
Secondary	Cerebrospinal Fluid (CSF) Pleocytosis	White blood cell count in CSF was measured at two time points, pre- and post-treatment

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	Cerebrospinal Fluid (CSF) Pleocytosis	White blood cell count in CSF was measured at two time points, pre- and post-treatment	19 treatment events in 16 patients at which both pre- and post-treatment CSF samples available.~The data are reported below, separately for pre-treatment samples and post-treatment samples.	cells/mm^3	MEDIAN
PRIMARY	Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus	through study completion, median 3 years of follow up		months	MEDIAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Cerebrospinal Fluid (CSF) Pleocytosis	Pre-treatment	3	Full Range 0 to 51	cells/mm^3
Cerebrospinal Fluid (CSF) Pleocytosis	Post-treatment	3	Full Range 0 to 41	cells/mm^3
Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus	Tacrolimus	48	95% Confidence Interval 22 to 72	months

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tacrolimus	26
Overall Study	COMPLETED	Tacrolimus	26
Overall Study	NOT COMPLETED	Tacrolimus	0

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Albumin, serum low	General disorders	All Patients	3	26	3
other	ALT, serum high	General disorders	All Patients	1	26	1
other	aspiration	Respiratory, thoracic and mediastinal disorders	All Patients	1	26	1
other	AST, serum high	General disorders	All Patients	1	26	1
other	BUN, serum high	General disorders	All Patients	4	26	6
other	calcium, serum low	General disorders	All Patients	2	26	2
other	constipation	Gastrointestinal disorders	All Patients	2	26	2
other	diarrhea	Gastrointestinal disorders	All Patients	2	26	2
other	dizziness	General disorders	All Patients	1	26	1
other	swallowing difficulty	Gastrointestinal disorders	All Patients	1	26	1

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Patients
Total, other adverse events	All Patients	10	26
Total, serious adverse events	All Patients	3	26

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22566506	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00378326

GET https://conductscience.org/api/trials/v1/NCT00378326/events?page=2

API reference For AI assistants